Clinical trial · Interventional
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Combination of DFMO and Sulindac to Decrease the Rate of Recurrence of Adenomatous Polyps in the Colon
NCT00118365CI-TRIAL-00016678completedPhase 3Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Precancerous Condition | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| eflornithine | Drug | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| placebo | Other | — | UNRESOLVED |
| sulindac | Drug | Sulindac | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- Arm II (placebo)
- description
- Patients receive oral double placebo once daily. In both arms, treatment continues for 36 months in the absence of unacceptable toxicity or the development of an invasive malignancy.
- interventionNames
- Other: placebo
- Other: laboratory biomarker analysis
- type
- EXPERIMENTAL
- label
- Arm I (eflornithine and sulindac)
- description
- Patients receive oral eflornithine (DFMO) and oral sulindac once daily. In both arms, treatment continues for 36 months in the absence of unacceptable toxicity or the development of an invasive malignancy.
- interventionNames
- Drug: eflornithine
- Drug: sulindac
- Other: laboratory biomarker analysis
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Criteria: * History of \>= 1 surgically resected adenomatous polyp of the colon measuring \>= 3 mm within the past 5 years * Screening colonoscopy performed within the past 6 months * All polyps must have been removed during colonoscopy, pathologically examined, and archived * No prior surgical resection removing \> 40 cm of the colon * No personal or family history of familial polyposis or hereditary non-polyposis colon cancer * SWOG 0-1 * Bilirubin =\< 2.0 mg/dL * AST and ALT =\< 2 times normal * Creatinine =\< 1.5 mg/dL * Urine protein =\<, urine casts 0-3, urine WBC and RBC count 0-5 cells by urinalysis * No history of inflammatory bowel disease * No gastric or duodenal ulcers within the past 12 months * Gastric or duodenal ulcers that were adequately treated \> 24 months ago are allowed * No symptomatic gastric or duodenal ulcers * Not pregnant or nursing * Negative pregnancy test * Must have regional geographic stability over the next 36 months * Pure tone audiometry evaluation normal * Patients with \>= 20 dB of uncorrectable hearing loss (for age) of any 2 contiguous frequencies are not allowed * No invasive malignancy within the past 5 years except adequately treated nonmelanoma skin cancer, level I (or Breslow \< 0.76 mm) cutaneous melanoma, Duke's A colon cancer, stage I cervical cancer, or stage 0 chronic lymphocytic leukemia * No severe metabolic disorder * No other significant acute or chronic disease that would preclude study participation * No history of abnormal wound healing or repair * No conditions that would confer risk of abnormal wound healing or repair * No history of allergy to NSAIDs or eflornithine * No concurrent chemotherapy * No concurrent corticosteroids on a regular or predictable intermittent basis * No concurrent radiotherapy * Concurrent calcium supplements (=\< 1,000 mg/day) allowed * Concurrent lipid-lowering drugs (i.e., high-dose statins) allowed * No other concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) on a regular or predictable intermittent basis * Concurrent aspirin for cardiovascular prophylaxis (i.e., 81 mg/day) allowed * No concurrent anticoagulants on a regular or predictable intermittent basis * No concurrent treatment for gastric or duodenal ulcers
References
Publications (1)
- DERIVEDThompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, Meyskens FL, Gerner EW. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology. 2010 Sep;139(3):797-805, 805.e1. doi: 10.1053/j.gastro.2010.06.005. Epub 2010 Jun 9. PMID 20538001